Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease

Edward V. Loftus, Scott J. Johnson, Si Tien Wang, Eric Wu, Parvez M. Mulani, Jingdong Chao

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Fingerprint

Dive into the research topics of 'Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease'. Together they form a unique fingerprint.

Medicine & Life Sciences